The physical, psychological and social impact of psoriasis
- PMID: 22013093
- DOI: 10.1177/135910539700200409
The physical, psychological and social impact of psoriasis
Abstract
Psoriasis is a chronic, disabling skin disease affecting up to 2 percent of the population. Little is known about how physical, psychological and social features of the illness interact to create a negative impact. In this article, a biopsychosocial model of the impact of psoriasis is described, and results from a survey of 317 psoriasis patients are presented. The types of functional disability, psychological distress and disease-related stressors are described for highly strained patients (i.e. those with disease-related suicidal ideation) and compared with less strained patients (i.e. those without suicidal ideation). As predicted by the model, significantly more disability, psychological distress and disease-related stressors are found among highly strained patients. Logistical regression analysis revealed that strain is more strongly associated with disability, distress and disease-related stress level than with disease severity. Implications for research and clinical interventions are discussed.
Similar articles
-
Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis.Br J Dermatol. 2005 Jun;152(6):1275-81. doi: 10.1111/j.1365-2133.2005.06565.x. Br J Dermatol. 2005. PMID: 15948993
-
Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress.Br J Dermatol. 1997 Nov;137(5):755-60. Br J Dermatol. 1997. PMID: 9415236
-
Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis.Br J Dermatol. 2006 Feb;154(2):325-31. doi: 10.1111/j.1365-2133.2005.06909.x. Br J Dermatol. 2006. PMID: 16433804
-
Quality-of-life issues in psoriasis.Dermatol Clin. 2004 Oct;22(4):389-95, viii. doi: 10.1016/j.det.2004.03.016. Dermatol Clin. 2004. PMID: 15450335 Review.
-
Psoriasis and vascular disease: an unsolved mystery.Am J Med. 2008 May;121(5):360-5. doi: 10.1016/j.amjmed.2008.01.025. Am J Med. 2008. PMID: 18456026 Review.
Cited by
-
Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation.Clinicoecon Outcomes Res. 2012;4:261-8. doi: 10.2147/CEOR.S35046. Epub 2012 Sep 13. Clinicoecon Outcomes Res. 2012. PMID: 23028233 Free PMC article.
-
Spotlight on Calcipotriol/Betamethasone Fixed-Dose Combination in Topical Formulations: Is There Still Room for Innovation?Pharmaceutics. 2022 Sep 29;14(10):2085. doi: 10.3390/pharmaceutics14102085. Pharmaceutics. 2022. PMID: 36297520 Free PMC article. Review.
-
Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials.Dermatol Ther (Heidelb). 2017 Sep;7(3):281-292. doi: 10.1007/s13555-017-0187-0. Epub 2017 Jun 21. Dermatol Ther (Heidelb). 2017. PMID: 28639011 Free PMC article. Review.
-
Trauma and Disfigurement: Psychosocial Impact and Ethical Reflections on esthetic Normalization in Medicine.Linacre Q. 2025 May 21:00243639251334426. doi: 10.1177/00243639251334426. Online ahead of print. Linacre Q. 2025. PMID: 40416417 Free PMC article.
-
Exploring genetic targets of psoriasis using genome wide association studies (GWAS) for drug repurposing.3 Biotech. 2020 Feb;10(2):43. doi: 10.1007/s13205-019-2038-4. Epub 2020 Jan 10. 3 Biotech. 2020. PMID: 31988837 Free PMC article.
LinkOut - more resources
Full Text Sources
Research Materials